Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991466 | 0.88 | L3MBTL1 (0.55) | NPC1RAB9AL3MBTL1MAPTEPHX2 | |
| SCHEMBL21991842 | 0.88 | L3MBTL1 (0.51) | NPC1RAB9AL3MBTL1MAPTEPHX2 | |
| SCHEMBL21991473 | 0.87 | EPHX2 (0.63) | NPC1RAB9AL3MBTL1MAPTEPHX2 | |
| SCHEMBL21991367 | 0.85 | EPHX2 (0.60) | NPC1RAB9AL3MBTL1MAPTEPHX2 | |
| SCHEMBL21991795 | 0.85 | EPHX2 (0.60) | NPC1RAB9AL3MBTL1MAPTEPHX2 | |
| SCHEMBL21992735 | 0.85 | EPHX2 (0.60) | NPC1RAB9AL3MBTL1MAPTEPHX2 | |
| SCHEMBL11462507 | 0.85 | EPHX2 (0.50) | MAPTEPHX2KMT2APOLBPPARG | |
| SCHEMBL21103699 | 0.85 | CYP1A2 (0.53) | L3MBTL1MAPTEPHX2KMT2APOLB | |
| SCHEMBL21991450 | 0.85 | CYP1A2 (0.53) | L3MBTL1MAPTEPHX2KMT2APOLB | |
| SCHEMBL21991768 | 0.84 | KMT2A (0.58) | MAPTEPHX2KMT2APOLBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | NPC1 233/4885RAB9A 1547/4885L3MBTL1 1170/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | NPC1 233/4885RAB9A 1547/4885L3MBTL1 1170/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | NPC1 233/4885RAB9A 1547/4885L3MBTL1 1170/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | NPC1 233/4885RAB9A 1547/4885L3MBTL1 1170/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | NPC1 233/4885RAB9A 1547/4885L3MBTL1 1170/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | NPC1 233/4885RAB9A 1547/4885L3MBTL1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.